Generic Name: Rimexolone
ATC Class: S01BA13
VA Class: OP300
Chemical Name: 11β-Hydroxy-16α, 17α-dimethyl-17-propionylandrosta-1,4-diene-3-one
Molecular Formula: C24H34O3
CAS Number: 49697-38-3
A synthetic nonfluorinated corticosteroid.
Uses for Vexol
Postoperative Ocular Inflammation
Treatment of postoperative ocular inflammation following ocular surgery (e.g., cataract extraction).a
Treatment of anterior uveitis.a
Vexol Dosage and Administration
Apply topically to the eye(s) as an ophthalmic suspension.a
Avoid contamination of preparation container.a
Shake suspension well before using.a
Do not administer rimexolone by injection.
Postoperative Ocular Inflammation
Instill 1 or 2 drops of 1% suspension into the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery and continuing for 2 weeks.a
Instill 1 or 2 drops of 1% suspension into the conjunctival sac of the affected eye(s) every hour while awake for 7 days, then 1 drop every 2 hours while awake for an additional 7 days.a
Duration of subsequent therapy depends on severity of the disease and response to therapy.
Gradually taper the dosage when the drug is discontinued to avoid exacerbation of the disease.
No special population dosage recommendations at this time.a
Cautions for Vexol
Risk of ocular hypertension or glaucoma (with damage to optic nerve), defects in visual acuity and fields of vision, and posterior subcapsular cataract formation with prolonged use of corticosteroids.a b c d e Use with caution in glaucoma because intraocular pressure (IOP) may increase.b c d e
See Contraindications under Cautions.
Prolonged use may suppress the host response and thus increase the risk of secondary ocular infections.a
In acute purulent conditions of the eye, corticosteroids may mask infection or enhance existing infection.a
Use of corticosteroids in the treatment of herpes simplex infections other than epithelial herpes simplex keratitis, in which corticosteroids are contraindicated, requires great caution; periodic slit-lamp microscopy is essential.a b
Evaluation of Ocular Condition
Initial prescription or renewal of medication order beyond 14 days should be provided only after examination of the patient with the aid of magnification (e.g., slit lamp biomicroscopy, fluorescein staining where appropriate).a
Reevaluate patient if improvement does not occur after 2 days.a
Long-term local corticosteroid application associated with development of fungal infections of the cornea.a Consider possibility of fungal infection in patients with persistent corneal ulceration who have been or are receiving corticosteroid therapy.a b
Safety and efficacy not established in pediatric patients.a
No substantial differences in safety and efficacy relative to younger adults.a
Common Adverse Effects
Extensively metabolized; metabolites are inactive or less active than the parent drug.a
Following IV administration in animals, 80% excreted in the feces as rimexolone and metabolites.a
Corticosteroids inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.a b
Presence of a methyl group at position C-21 may reduce the risk of increased IOP associated with topical ophthalmic corticosteroid therapy.
Advice to Patients
Importance of informing a clinician if an intercurrent ocular condition (e.g., trauma, surgery, infection) develops during ophthalmic therapy.b
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.a
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.a
Importance of informing patients of other important precautionary information.a (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Vexol (with benzalkonium chloride)
AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions June 1, 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
a. Alcon Laboratories. Vexol (rimexolone) 1% ophthalmic suspension prescribing information. Fort Worth, TX; 2003 Jun.
b. AHFS drug information 2007. McEvoy GK, ed. EENT corticosteroids general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2007:2813-5.
c. Allergan, Inc. Blephamide (sulfacetamide sodium and prednisolone acetate) ophthalmic ointment prescribing information. Irvine, CA; 2004 Sep.
d. Allergan, Inc. FML Forte (fluorometholone) ophthalmic suspension prescribing information. Irvine, CA; 2004 Jun.
e. Bausch & Lomb. Alrex (loteprednol etabonate) ophthalmic suspension prescribing information. Tampa, FL; 2006 Apr.